Tvardi Therapeutics Reports Improved Q1 Net Loss, Extends Cash Runway, and Outlines Key Clinical Milestones
Summary
Tvardi Therapeutics announced improved Q1 2026 financial results, extended its cash runway into Q4 2026, and provided updates on key clinical development milestones for TTI-109 and TTI-101.
Key Events
-
Improved Q1 Net Loss
The company reported a net loss of $6.8 million for Q1 2026, an improvement compared to a $9.6 million net loss in the prior year period.
-
Extended Cash Runway
Tvardi Therapeutics anticipates its current cash of $25.0 million (as of March 31, 2026) is sufficient to fund operations through clinical readouts and into the fourth quarter of 2026, addressing near-term liquidity concerns.
-
Upcoming TTI-109 Clinical Data
Topline data from the healthy volunteer study for TTI-109, a next-generation STAT3 inhibitor, and its clinical development strategy are expected in June 2026.
-
TTI-101 HCC Data On Track
Topline results from the Phase 1b/2 REVERT LIVER CANCER trial for TTI-101 in hepatocellular carcinoma (HCC) remain on track for the second half of 2026.
Analysis
This filing provides the detailed Q1 2026 financial results and a crucial business update. The reported net loss of $6.8 million is an improvement over the prior year, and the company has extended its cash runway into the fourth quarter of 2026. This extension is particularly important given the previously disclosed going concern warning in the concurrently filed 10-Q, providing investors with a clearer near-term financial outlook. Additionally, the company highlighted significant upcoming clinical catalysts for its TTI-109 and TTI-101 programs, which are critical value drivers for a clinical-stage biopharmaceutical company.
At the time of this filing, TVRD was trading at $4.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.5M. The 52-week trading range was $2.75 to $43.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.